Drug
D0805 | bisacodyl
A
A06AG02 Bisacodyl
[A06AG] Enemas
[A06A] DRUGS FOR CONSTIPATION
[A06] DRUGS FOR CONSTIPATION
[A] Alimentary tract and metabolism
A06AB52 Bisacodyl, combinations
[A06AB] Contact laxatives
[A06A] DRUGS FOR CONSTIPATION
[A06] DRUGS FOR CONSTIPATION
[A] Alimentary tract and metabolism
A06AB02 Bisacodyl
[A06AB] Contact laxatives
[A06A] DRUGS FOR CONSTIPATION
[A06] DRUGS FOR CONSTIPATION
[A] Alimentary tract and metabolism
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 14.82±3.63 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 7.74 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 18.39±13.00 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 312.4 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | EC20 | 36 |
| RESPIRATION | 50.9 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | decrease | EC20 | 36 |
| RESPIRATION | 52.5 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | decrease | EC20 | 36 |
| SWELLING | > 400 µM | 30 mins | mouse | liver mitochondria | swelling assay: Absorbance at 545 nm using a fluorescence multi-well plate reader (CaCl2 (50 µM) was considered as the 100% baseline for the swelling ) | increase | EC20 | 36 |
| Target | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| NADH:ubiquinone reductase | 50.9 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | inhibit | EC20 | 36 |
| Succinate dehydrogenase | 52.5 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | inhibit | EC20 | 36 |
| Cytochrome c | > 400 µM | 30 mins | mouse | liver mitochondria | Cytochrome c release was evaluated using ELISA kit ( 20 µg/ml Alamethicin was used as 100% baseline) | release | EC20 | 36 |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
 |
Warning |
Aggregated GHS information provided by 56 companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (10.71%): Harmful if swallowed [Warning Acute toxicity, oral] H315 (94.64%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (96.43%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H335 (83.93%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure Respiratory tract irritation] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | intraperitoneal | 983mg/kg (983mg/kg) | Blood. Vol. 76, Pg. 2389, 1990. | |
| rat | LD50 | oral | 2gm/kg (2000mg/kg) | cardiac: other changes | Archives of Toxicology, Supplement. Vol. 18, Pg. 202, 1996. |
| rat | LD50 | intraperitoneal | 600mg/kg (600mg/kg) | Drugs of the Future. Vol. 13, Pg. 413, 1988. | |
| mammal (species unspecified) | LD50 | unreported | > 1gm/kg (1000mg/kg) | Archives of Toxicology, Supplement. Vol. 18, Pg. 202, 1996. | |
| guinea pig | LDLo | oral | 1gm/kg (1000mg/kg) | BioMetals. Vol. 10, Pg. 247, 1997. | |
| (4,4'-Diacetoxydiphenyl)(2-pyridyl)methane | (Pyridin-2-ylmethylene)bis(4,1-phenylene) diacetate | (pyridin-2-ylmethanediyl)dibenzene-4,1-diyl diacetate |
| (pyridin-2-ylmethylene)di-4,1-phenylene diacetate | 10X0709Y6I | 2-(4,4'-Diacetoxydiphenylmethyl)pyridine |
| 4,4'-(2-Pyridylmethylene)bisphenol diacetate | 4,4'-(2-Pyridylmethylene)diphenol diacetate | 4,4'-(2-Pyridylmethylene)diphenol diacetate (ester) |
| 4,4'-(2-pyridylmethylene)bisphenol diacetate | 4,4'-(pyridin-2-ylmethylene)bis(4,1-phenylene) diacetate | 4,4'-Diacetoxydiphenylpyrid-2-ylmethane |
| 4,4'-Diacetoxydiphenylpyridyl-2-methane | 4,4-(2-Pyridylmethylene)diphenol diacetate | 4-[(4-acetyloxyphenyl)-2-pyridylmethyl]phenyl acetate |
| 4-[[4-(Acetyloxy)phenyl](2-pyridinyl)methyl]phenyl acetate # | 4-[[4-(acetyloxy)phenyl](2-pyridyl)methyl]phenyl acetate | 603-50-9 |
| A14914 | A832704 | AB00051928 |
| AB00051928-17 | AB00051928_18 | AB00051928_19 |
| AC-24284 | AK116442 | AKOS001599884 |
| API0001726 | AS-15820 | AX8117347 |
| B1898 | B5066 | BCP18567 |
| BDBM61400 | BPBio1_000416 | BRD-K39987650-001-05-0 |
| BRD-K39987650-001-15-9 | BRN 0323727 | BSPBio_000378 |
| BSPBio_001916 | Bicol | Bis(p-acetoxyphenyl)-2-pyridylmethane |
| Bisacodilo | Bisacodilo [INN-Spanish] | Bisacodyl (JP17/USP/INN) |
| Bisacodyl [USAN:INN:BAN:JAN] | Bisacodyl [USP:INN:BAN:JAN] | Bisacodyl for peak identification, European Pharmacopoeia (EP) Reference Standard |
| Bisacodyl for system suitability, European Pharmacopoeia (EP) Reference Standard | Bisacodyl, European Pharmacopoeia (EP) Reference Standard | Bisacodyl, United States Pharmacopeia (USP) Reference Standard |
| Bisacodyl, active ingredient of Viraplex | Bisacodyl, analytical standard, for drug analysis | Bisacodyl,(S) |
| Bisacodylum | Bisacodylum [INN-Latin] | Brocalax |
| C22H19NO4 | CAS-603-50-9 | CCG-35661 |
| CCG-36442 | CCRIS 8864 | CHEBI:3125 |
| CHEMBL942 | CS-2667 | CTK8F8189 |
| Correctol Tablets, Caplets | D00245 | DB09020 |
| DSSTox_CID_2681 | DSSTox_GSID_22681 | DSSTox_RID_76689 |
| DTXSID1022681 | Deficol | Di-(4-acetoxyphenyl)-2-pyridylmethane |
| Di-(p-acetoxyphenyl)-2-pyridylmethane | DivK1c_000347 | Dulcolan |
| Dulcolax | Dulcolax | Dulcolax (TN) |
| Durolax | EBD8044 | EINECS 210-044-4 |
| Endokolat | Eulaxan | FT-0603486 |
| Feen-a-Mint Tablets | Fenilaxan | Godalax |
| HMS1569C20 | HMS1920G21 | HMS2090K15 |
| HMS2091O03 | HMS2096C20 | HMS2235I11 |
| HMS3373L17 | HMS3652E04 | HMS3713C20 |
| HMS501B09 | HSDB 3016 | HY-B0557 |
| HalfLytely | HalfLytely (Salt/Mix) | Hillcolax |
| Horton | IDI1_000347 | Ivilax |
| KBio1_000347 | KBio2_000506 | KBio2_003074 |
| KBio2_005642 | KBio3_001416 | KBioGR_000692 |
| KBioSS_000506 | KHOITXIGCFIULA-UHFFFAOYSA-N | KS-00000FS0 |
| LA96a | LACO | LS-2218 |
| Laxadin | Laxanin N | Laxans |
| Laxine | Laxorex | MCULE-8607347748 |
| MFCD00038039 | MLS000069729 | MLS002701749 |
| NCGC00016522-01 | NCGC00016522-02 | NCGC00016522-03 |
| NCGC00016522-04 | NCGC00016522-05 | NCGC00016522-06 |
| NCGC00016522-07 | NCGC00016522-08 | NCGC00016522-09 |
| NCGC00016522-10 | NCGC00016522-11 | NCGC00016522-12 |
| NCGC00023260-03 | NCGC00023260-04 | NCGC00023260-05 |
| NCGC00023260-06 | NCGC00257892-01 | NCI60_004954 |
| NCIChal_000004 | NCIMech_000456 | NINDS_000347 |
| NSC-614826 | NSC-755914 | NSC614826 |
| NSC755914 | Neolax | Nigalax |
| Opera_ID_884 | Pharmakon1600-01500147 | Phenol, 4,4'-(2-pyridinylmethylene)bis-, 1,1'-diacetate |
| Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate | Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester) | Phenol, 4,4'-(2-pyridylmethylene)di-, diacetate |
| Phenol, 4,4'-(2-pyridylmethylene)di-, diacetate (ester) | Phenol,4'-(2-pyridinylmethylene)bis-, diacetate (ester) | Prestwick0_000419 |
| Prestwick1_000419 | Prestwick2_000419 | Prestwick3_000419 |
| Prestwick_780 | Pyrilax | Q-200726 |
| Q-200727 | Q417874 | REGID_for_CID_2391 |
| SBB057015 | SBI-0051297.P003 | SC-18411 |
| SCHEMBL21044 | SMR000058226 | SPBio_000258 |
| SPBio_002317 | SPECTRUM1500147 | SR-01000000233 |
| SR-01000000233-2 | SR-01000000233-3 | ST024745 |
| ST24026365 | STK293202 | SW196918-3 |
| Sanvacual | Sk-bisacodyl | Spectrum2_000149 |
| Spectrum3_000318 | Spectrum4_000256 | Spectrum5_000898 |
| Spectrum_000086 | Stadalax | Telemin |
| Theralax | Tox21_110472 | Tox21_110472_1 |
| Tox21_200338 | UNII-10X0709Y6I | Ulcolax |
| ZINC3830321 | Zetrax | [4-[(4-Acetyloxyphenyl)-pyridin-2-ylmethyl]phenyl] acetate; |
| [4-[(4-acetyloxyphenyl)-pyridin-2-yl-methyl]phenyl] ethanoate | [4-[(4-acetyloxyphenyl)-pyridin-2-ylmethyl]phenyl] acetate | acetic acid [4-[(4-acetyloxyphenyl)-(2-pyridinyl)methyl]phenyl] ester |
| bisacodyl | cid_2391 | s4047 |